<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928379</url>
  </required_header>
  <id_info>
    <org_study_id>17011</org_study_id>
    <secondary_id>I8P-MC-OXAD</secondary_id>
    <secondary_id>2018-004779-11</secondary_id>
    <nct_id>NCT03928379</nct_id>
  </id_info>
  <brief_title>A Study of LY3305677 in Participants With Type 2 Diabetes</brief_title>
  <official_title>A Multiple-Ascending Dose Study in Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety and side effects of
      LY3305677 when it is given as an injection just under the skin to participants with type 2
      diabetes. The study will last about 20 weeks for each participant, not including screening.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Enrollment on hold due to COVID-19 pandemic.
  </why_stopped>
  <start_date type="Actual">October 27, 2019</start_date>
  <completion_date type="Anticipated">November 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Baseline through 20 weeks</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3305677</measure>
    <time_frame>Baseline through 48 hours postdose</time_frame>
    <description>PK: Cmax of LY3305677</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration-Time Curve (AUC) of LY3305677</measure>
    <time_frame>Baseline through 48 hours postdose</time_frame>
    <description>PK: AUC of LY3305677</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose</measure>
    <time_frame>Baseline, through Week 12</time_frame>
    <description>PD: Change from Baseline in Fasting Plasma Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change from Baseline in Fasting Plasma Insulin</measure>
    <time_frame>Baseline, through Week 12</time_frame>
    <description>PD: Change from Baseline in Fasting Plasma Insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY3305677</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3305677 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3305677</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3305677</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have Type II diabetes

          -  Body mass index (BMI) of 25-40 kilograms per square meter (kg/m²), inclusive

          -  Have a body weight of &lt;150 kilograms (kg)

          -  Have clinical lab test results within normal reference range for the population or
             investigator site, or results with acceptable deviations that are judged to be not
             clinically significant by the investigator; however, should have serum magnesium and
             potassium levels, along with lactate dehydrogenase, CK values within the normal range
             at screening and Day -2.

        Exclusion Criteria:

          -  Have Type 1 diabetes or latent autoimmune diabetes in adults

          -  Have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state
             requiring hospitalization for 6 months prior to screening

          -  Have had an episode of severe hypoglycemia, defined by the occurrence of
             neuroglycopenic symptoms requiring the assistance of another person for recovery,
             within 6 months prior to Visit 1

          -  Have an abnormal 12-lead electrocardiogram (ECG) at screening and/or Day -2 that, in
             the opinion of the investigator, increases the risks associated with participating in
             the study or may confound ECG data analysis

          -  Have poorly controlled hypertension at screening; or a change in antihypertensive
             medication within 30 days of screening

          -  Have an estimated glomerular filtration rate &lt;45 milliliters per minute per 1.73
             meters squared of body surface area (mL/min/1.73 m²)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

